TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02533947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention consists of an individually tailored supervised exercise program with aerobic, strength and coordinative components.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: A waitlist control group will get the intervention after 7 month of treatment as usual.
Study: NCT03904433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil
Description: Coconut oil given in coffee with cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil
Description: Coconut oil given in coffee with cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil
Description: Coconut oil given in coffee with cream

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caprylic acid
Description: Caprylic acid given in coffee with cream
Study: NCT01106014

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching selexipag
Study: NCT03904433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caprylic acid
Description: Caprylic acid given in coffee with cream

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caprylic acid
Description: Caprylic acid given in coffee with cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Description: Sunflower oil given in coffee with cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Description: Sunflower oil given in coffee with cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Description: Sunflower oil given in coffee with cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose dissolved in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose dissolved in water
Study: NCT02370979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Study: NCT04247581

Intervention type: DEVICE
Group type: OTHER
Intervention: 1-lead ECG
Description: 1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions.

Intervention type: DEVICE
Group type: OTHER
Intervention: 1-lead ECG
Description: 1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions.
Study: NCT02710045

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles Vaccine at 9 months of age
Description: Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles Vaccine at 9 months of age
Description: Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP Vaccine at 9 months of age
Description: Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP Vaccine at 9 months of age
Description: Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles Vaccine at 18 months of age
Description: Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles Vaccine at 18 months of age
Description: Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles Vaccine at 18 months of age
Description: Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
Study: NCT02166554

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: On the day of initial surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linked Hyaluronan Hydrogel
Description: On the day of the initial surgery
Study: NCT00686842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGF inhibitor PTC299
Description: 20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
Study: NCT01291758

Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal bicycle exercise stress tests performed 24 hr apart
Description: Submaximal bicycle exercise stress tests were performed for 25 min at 70% predicted heart rate, then ramped up to 85% predicted heart rate. Subjects could stop when they felt they had reached their maximum effort if before reaching 85% predicted heart rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal bicycle exercise stress tests performed 24 hr apart
Description: Submaximal bicycle exercise stress tests were performed for 25 min at 70% predicted heart rate, then ramped up to 85% predicted heart rate. Subjects could stop when they felt they had reached their maximum effort if before reaching 85% predicted heart rate.
Study: NCT00686842

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
Study: NCT03620045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute moderate physical activity
Description: For 20 minutes, participants will walk on a treadmill at a moderate intensity based on a combination of evidence-based and pre-determined parameters, including ratings of perceived exertion and heart rate
Study: NCT01670591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PS - Prevention in School
Study: NCT00686842

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
Study: NCT04382573

Intervention type: GENETIC
Intervention: Epigenetic signatures
Description: Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
Study: NCT05938933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHP
Description: personalized health planning (PHP)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMA
Description: shared medical appointments (SMAs)
Study: NCT01747941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: single dose, solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: single dose, solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: single dose, solution
Study: NCT00651326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flutamide
Study: NCT00686842

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
Study: NCT01430676

Intervention type: PROCEDURE
Intervention: differences in surgical techniques
Description: follow the risk for morbidity after incisional hernia repair
Study: NCT03278431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole (400 mg) from Janssen, donated by the World Health Organization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole (400 mg) from Janssen, donated by the World Health Organization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrantel Pamoate
Description: Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrantel Pamoate
Description: Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrantel Pamoate
Description: Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxantel Pamoate
Description: Oxantel pamoate (20mg/kg) will be produced by the University of Basel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxantel Pamoate
Description: Oxantel pamoate (20mg/kg) will be produced by the University of Basel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxantel Pamoate
Description: Oxantel pamoate (20mg/kg) will be produced by the University of Basel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxantel Pamoate
Description: Oxantel pamoate (20mg/kg) will be produced by the University of Basel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
Study: NCT04149574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Specified Dose on Specified Days
Study: NCT01983280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healing Touch
Study: NCT03432416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NES-E2 CVR
Description: NES-E2 CVR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NES-E2 CVR
Description: NES-E2 CVR
Study: NCT04342689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary Supplement containing resistant starch
Description: Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Starch
Description: Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
Study: NCT00205543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uvulopalatopharyngoplasty with or without sutures
Description: standard UPPP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uvulopalatopharyngoplasty with or without sutures
Description: standard UPPP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uvulopalatopharyngoplasty with or without sutures
Description: standard UPPP
Study: NCT00573807

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
Study: NCT02977845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients.
Study: NCT00254683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT with FDG
Description: PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
Study: NCT02279836

Intervention type: DEVICE
Group type: OTHER
Intervention: SC20 Colonoscope
Description: Single Arm Post-Marketing Study of SC20 Colonoscope
Study: NCT03442517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Lifestyle Intervention
Description: Participants will be involved in group-based counseling. Sessions will be about 1 hour each and comprise up to 10 people. The sessions will be led by a trained health educator. The calls will be a chance for participants to discuss challenges with breastfeeding, problem solving skills, educational information, and discuss balanced diet topics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual prenatal care
Description: Participants will receive the standard education given by their OBGYN or other healthcare provider. No additional breastfeeding, nutrition or postpartum weight loss education will be provided to participants by the investigators during pregnancy. After delivery, participants will follow normal pediatric visit schedule.
Study: NCT02152514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine/Sufentanil
Study: NCT03915509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis
Description: Lasak Impladent Implants (sandblasted)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis
Description: Lasak Impladent Implants (sandblasted)
Study: NCT01747941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study: NCT00651326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Study: NCT02152514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCA

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PCA
Study: NCT04168008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WISH Adherence
Description: The educational sessions will consist of an adherence-centered curriculum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WISH Parenting
Description: The educational sessions will focus on parenting and baby care.
Study: NCT01119365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Light is administered through a custom designed mask with LED lights.
Study: NCT02114385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: 9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL
Description: Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
Study: NCT04593576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity protocol/out door sports
Description: Warm up exercise will be administered for 10 minutes, then one-to-five small group of instruction based activity will be administered for 15 minutes. After this whole group will be engaged in ball exercise and cooperative ball games for 20 minutes. At the end cool down and reward activity will be done with participants for 15v minutes.~Total 1 hour physical activity protocol will be administered twice a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive table teaching speech therapy
Description: Control group participants will be given speech therapy session based on intensive table teaching for 30 minutes twice a week.
Study: NCT00549679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256066
Description: PDE4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256066
Description: PDE4 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02694328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Daily dosing
Study: NCT04060446

Intervention type: DEVICE
Intervention: Medical Device
Description: Smoke cigarettes with CReSSMicro topography measurement device and BioRadio device

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Intervention: Tobacco Smoking
Description: Smoke cigarettes
Study: NCT04400786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent treatment
Description: According to the feeling of pain, the on-demand treatment group is prescribed with or without Imrecoxib (100mg/tablet, 100mg.prn.po), but the maximal dose does not exceed 100 mg per time, twice (morning and evening) per day. The duration lasted for 24 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous treatment
Description: The continuous treatment group is prescribed Imrecoxib (100mg.bid.po) regardless of the pain in the treatment course for 24 weeks.
Study: NCT03953573

Intervention type: OTHER
Intervention: Survey
Description: Survey completed at 1 day, 8 days 1 or 3 months post delivery
Study: NCT03394287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study: NCT02627430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 Inhibitor AT13387
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study: NCT04495842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Oil Blend
Description: 5 drops of on a tester strip

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Blend
Description: 5 drops on a tester strip
Study: NCT01382446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: 0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste
Description: Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
Study: NCT03930043

Intervention type: DIAGNOSTIC_TEST
Intervention: Metagenomic shotgun sequencing
Description: preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen

Intervention type: DIAGNOSTIC_TEST
Intervention: Metagenomic shotgun sequencing
Description: preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen
Study: NCT00927615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab
Description: 0.25 mg/kg body weight (intracoronary)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abciximab
Description: 0.25 mg/kg body weight (intravenous)